In the cohort of 217 CRC samples, 61.6% (n = 134) exhibited high EZH2 immunostaining, and 38.4% (n = 83) exhibited low EZH2 immunostaining (Supplementary Figure 2H). This evidence concerns the gene EZH2 and colorectal carcinoma.